Stage 4 EGFR-Positive Lung Cancer Treatment: How ECCT Helps

A year ago, Mrs. Rika was repeatedly hospitalized due to lung cancer. She was even admitted to the ICU for 5 days. A CT scan showed a large cancer mass that had spread extensively to both lungs, her bones, and her brain, leaving her unable to get up and fully dependent on an oxygen tube. The biopsy revealed adenocarcinoma with a positive EGFR mutation. Medically, Stage 4 EGFR-Positive Lung Cancer Treatment can respond to targeted therapy with tyrosine kinase inhibitors, but studies show that even with targeted drugs, the average survival is only about 4–12 months.

Her husband consulted about the possibility of using the ECCT device while she was still in the hospital. However, because her condition was very weak, unable to get up and still reliant on oxygen, she still needed medical care. They choose to combining ECCT with targeted therapy as prescribed by her doctor, to help suppress excessive immune responses caused by the large number of dead cells in the early stages of treatment with electric fields.

Mrs. Rika continued to be hospitalized on and off even after starting ECCT, which made it difficult for her to use the device optimally. Her condition only began to improve after about a month of use, her breathing gradually became easier, her back pain lessened, she was able to get up on her own, and eventually she stopped going in and out of the hospital. At home, she gradually returned to normal activities and was able to wean off the oxygen tube.

A PET scan after about 4 months of treatment showed significant shrinkage of the cancer mass. The spread to her right lung, bones, and brain had disappeared on PET and MRI scans. Only a residual mass in the left lung remained, along with a cyst in her liver that showed little change.

After 1 year of ECCT use, she still maintained her ECCT usage beyond 15 minutes twice a day only. Even so, her condition was relatively normal. A CT scan showed only a thin residual mass in her left lung, mostly scar tissue like the remnants of old wounds.